Introduction: Vertebral fractures are the most common osteoporotic fracture and may result in back pain with functional limitations and diminished quality of life. Teriparatide [rhPTH (1–34)] has been shown to increase bone mass and reduce the risk of vertebral and other osteoporotic fractures. Materials and Methods: From January 2006 to January 2008 thirty women (mean age 72.3) with osteoporotic compression vertebral fractures (VCF) have been treated with a daily subcutaneous administration of teriparatide (20 μg/day) and supplementation with calcium and vitamin D. All patients underwent a preliminary clinical (VAS, Oswestry Disability Index) and instrumental evaluation (Plain X-ray with vertebral morphometry and DXA). Inclusion criteria were: persistent back pain non responsive to drugs, postmenopausal osteoporosis, a minimum of one year previous antiresorptive therapy. Results: The mean pre-treatment VAS and ODI scores were 8.3 and 78% respectively. In all patients plain X-rays have shown at least one severe vertebral fracture (>40%) with a mean (Bone Mineral Density) T-score of -3.8 at lumbar spine. Clinical and instrumental evaluation was performed at 6, 12 and 18 months. The mean VAS score was 4.2, 4 and 4.4 respectively as well as the ODI score with 55, 50 and 50%. No statistically significative T-score improvement was observed in any patients at every step of follow up.Conclusion: Chronic back pain associated with vertebral fracture provides a great challenge to physicians and patients. A daily administration of teriparatide is a valid a reliable treatment of severe osteoporosis with VCF. Despite a dramatic improvement in VAS and ODI score no significative BMD modification was observed during follow up.

CLINICAL IMPROVEMENT AFTER 18 MONTH OF THERAPY WITH TERIPARATIDE IN PATIENTS AFFECTED BY OSTEOPOROTIC VERTEBRAL FRACTURE: OUR EXPERIENCE IN THIRTY WOMEN TREATED / Doria, C; Milia, F; Tidu, L; Ruggiu, A; Zachos, A; Tranquilli Leali, P. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 19:suppl 2(2008), pp. S 449-S 450. [10.1007/s00198-008-0736-6]

CLINICAL IMPROVEMENT AFTER 18 MONTH OF THERAPY WITH TERIPARATIDE IN PATIENTS AFFECTED BY OSTEOPOROTIC VERTEBRAL FRACTURE: OUR EXPERIENCE IN THIRTY WOMEN TREATED

Doria C;Tranquilli Leali P
2008-01-01

Abstract

Introduction: Vertebral fractures are the most common osteoporotic fracture and may result in back pain with functional limitations and diminished quality of life. Teriparatide [rhPTH (1–34)] has been shown to increase bone mass and reduce the risk of vertebral and other osteoporotic fractures. Materials and Methods: From January 2006 to January 2008 thirty women (mean age 72.3) with osteoporotic compression vertebral fractures (VCF) have been treated with a daily subcutaneous administration of teriparatide (20 μg/day) and supplementation with calcium and vitamin D. All patients underwent a preliminary clinical (VAS, Oswestry Disability Index) and instrumental evaluation (Plain X-ray with vertebral morphometry and DXA). Inclusion criteria were: persistent back pain non responsive to drugs, postmenopausal osteoporosis, a minimum of one year previous antiresorptive therapy. Results: The mean pre-treatment VAS and ODI scores were 8.3 and 78% respectively. In all patients plain X-rays have shown at least one severe vertebral fracture (>40%) with a mean (Bone Mineral Density) T-score of -3.8 at lumbar spine. Clinical and instrumental evaluation was performed at 6, 12 and 18 months. The mean VAS score was 4.2, 4 and 4.4 respectively as well as the ODI score with 55, 50 and 50%. No statistically significative T-score improvement was observed in any patients at every step of follow up.Conclusion: Chronic back pain associated with vertebral fracture provides a great challenge to physicians and patients. A daily administration of teriparatide is a valid a reliable treatment of severe osteoporosis with VCF. Despite a dramatic improvement in VAS and ODI score no significative BMD modification was observed during follow up.
2008
CLINICAL IMPROVEMENT AFTER 18 MONTH OF THERAPY WITH TERIPARATIDE IN PATIENTS AFFECTED BY OSTEOPOROTIC VERTEBRAL FRACTURE: OUR EXPERIENCE IN THIRTY WOMEN TREATED / Doria, C; Milia, F; Tidu, L; Ruggiu, A; Zachos, A; Tranquilli Leali, P. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 19:suppl 2(2008), pp. S 449-S 450. [10.1007/s00198-008-0736-6]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/46871
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact